4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-022648
CHIEF SCIENTIFIC OFFICER sold 12,500 shares at an average $19.86 ($248,217)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-08-19 | Sale : show line 1 in the form 10b5-1 | −5,000 | $19.62 | $98,118 | 947,688 | I |
| 2025-08-21 | Sale : show line 2 in the form 10b5-1 | −7,500 | $20.01 | $150,099 | 940,188 | I |
| Open-market sales · 12,500 sh · avg $19.86 · $248,217 | ||||||
Loading xslF345X05/form4-08212025_100834.xml…